Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech Seeks Licensee for Therapeutic siRNA Delivery Technology

Premium

By Doug Macron

Life Technologies this week announced that it is seeking a licensee for a therapeutic siRNA-delivery technology that the company says is up to 100 times more potent that its research-only delivery reagents.

According to Xavier de Mollerat du Jeu, senior staff scientist at Life Tech, Invitrogen — which merged with Applied Biosystems in late 2008 to form Life Technologies — had for several years been developing delivery agents that could enable in vivo RNAi research experiments. It introduced the lipid-based agent Invivofectamine in late 2008 and then launched a follow-on product, Invivofectamine 2, two years later.

In the course of developing these and other research reagents, Life Tech's scientists discovered a “new class of [lipid] molecules of extremely high potency and [which] perform 100-fold better than Invivofectamine II,” he said.

He declined to provide specific details on the performance of the delivery vehicle, but said that “it's very comparable to some of the best molecules that Alnylam and Tekmira have.”

For instance, in in vivo testing, siRNAs against factor VII and delivered using the reagent could achieve 50 percent target inhibition at doses of 0.0125 mg/kg. With optimal siRNAs, inhibition of greater than 90 percent could be achieved, although the required dose was higher, de Mollerat du Jeu noted.

The delivery vehicle also has a very favorable toxicity profile, he said, although he did not elaborate.

Maya Tanaka, senior manager of business development and licensing, added that Life Tech has a data package on the technology that will be made available to potential licensees that contact the company directly.

She said that the company has not decided on whether it will license the technology in its entirety or on a target-by-target basis.

“Right now, we are speaking to a number of companies to see what the interest is,” she said. “We're open to a lot of different options and proposals.”


Have topics you'd like to see covered in Gene Silencing News? Contact the editor
at dmacron [at] genomeweb [.] com

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.